Medicare Spending on Drugs and Biologics Not Recommended for Coverage by International Health Technology Assessment Agencies

Lignende værker

• Medicare Spending and Potential Savings on Brand-Name Drugs With Available Generic Substitutes Excluded by 2 Large Pharmacy Benefit Managers, 2012 Through 2015
  af: Egilman, Alexander C., et al.
  Udgivet: (2018)
• Medicare Formulary Coverage and Restrictions for Opioid Potentiators from 2013 to 2017
  af: Vijay, Aishwarya, et al.
  Udgivet: (2019)
• Medicare Formulary Coverage of Brand-Name Drugs and Therapeutically Interchangeable Generics
  af: Vijay, Aishwarya, et al.
  Udgivet: (2019)
• Prescription Drug Coverage and Spending for Medicare Beneficiaries
  af: Poisal, John A., et al.
  Udgivet: (1999)
• Validity of Surrogate Endpoints and Their Impact on Coverage Recommendations: A Retrospective Analysis across International Health Technology Assessment Agencies
  af: Ciani, Oriana, et al.
  Udgivet: (2021)